NAS:RANI (USA)
Â
Class A
$
0.70
+0.019 (+2.89%)
07:08 PM EST
Business Description
Rani Therapeutics Holdings Inc
NAICS : 541713
SIC : 2833
ISIN : US7530181004
Share Class Description:
RANI: Class ATotal Employee Number:
69Description
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.01 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.12 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.34 | |||||
Beneish M-Score | -1.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 39.9 | |||||
3-Year EPS without NRI Growth Rate | 29.9 | |||||
3-Year FCF Growth Rate | 48 | |||||
3-Year Book Growth Rate | -38.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.24 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 86.07 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.25 | |||||
9-Day RSI | 39.47 | |||||
14-Day RSI | 38.86 | |||||
3-1 Month Momentum % | -17.45 | |||||
6-1 Month Momentum % | -42.04 | |||||
12-1 Month Momentum % | 86.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.4 | |||||
Quick Ratio | 3.4 | |||||
Cash Ratio | 3.13 | |||||
Days Sales Outstanding | 179.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -56.9 | |||||
Shareholder Yield % | 25.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1092.96 | |||||
Net Margin % | -929.06 | |||||
EBITDA Margin % | -1053.33 | |||||
FCF Margin % | -540.04 | |||||
OCF Margin % | -538.4 | |||||
ROE % | -327.69 | |||||
ROA % | -91.06 | |||||
ROIC % | -188.4 | |||||
3-Year ROIIC % | 491.42 | |||||
ROC (Joel Greenblatt) % | -653.4 | |||||
ROCE % | -227.2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 28.81 | |||||
PB Ratio | 2.38 | |||||
Price-to-Tangible-Book | 2.4 | |||||
EV-to-EBIT | -1.33 | |||||
EV-to-EBITDA | -1.36 | |||||
EV-to-Revenue | 14.31 | |||||
EV-to-Forward-Revenue | 5.3 | |||||
EV-to-FCF | -2.65 | |||||
| Price-to-Net-Current-Asset-Value | 2.9 | |||||
| Price-to-Net-Cash | 3.48 | |||||
Earnings Yield (Greenblatt) % | -75.19 | |||||
FCF Yield % | -22.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RANI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rani Therapeutics Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.169 | ||
| EPS (TTM) ($) | -0.41 | ||
| Beta | 2.1171 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.76 | ||
| Volatility % | 353.39 | ||
| 14-Day RSI | 38.86 | ||
| 14-Day ATR ($) | 0.05588 | ||
| 20-Day SMA ($) | 0.72079 | ||
| 12-1 Month Momentum % | 86.29 | ||
| 52-Week Range ($) | 0.416 - 3.87 | ||
| Shares Outstanding (Mil) | 112.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rani Therapeutics Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rani Therapeutics Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 108 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 17 days | ||
| General meeting for 2026 | 2026-05-28 08:00 | 0.95 (+3.83%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 10:00 | 0.97 (-8.27%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.11 (+4.72%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 16:30 | 1.14 (+5.56%) | ||
| Annual report for 2025 | 2026-03-26 | 1.14 (+5.56%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 1.14 (+5.56%) | ||
| Guidance call for 2025 | 2025-12-03 08:45 | 1.38 (-8.61%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 2.50 (+2.46%) |
Show
Entries
Rani Therapeutics Holdings Inc Frequently Asked Questions
What is Rani Therapeutics Holdings Inc(RANI)'s stock price today?
The current price of RANI is $0.70. The 52 week high of RANI is $3.87 and 52 week low is $0.42.
When is next earnings date of Rani Therapeutics Holdings Inc(RANI)?
The next earnings date of Rani Therapeutics Holdings Inc(RANI) is 2026-08-07 Est..
Does Rani Therapeutics Holdings Inc(RANI) pay dividends? If so, how much?
Rani Therapeutics Holdings Inc(RANI) does not pay dividend.
Guru Commentaries on NAS:RANI
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) | 2024-01-09 |
Articles on Rani Therapeutics Holdings Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers